Evaluate the Post-marketing Efficacy and Safety of Eptq S and Eptq Lidocaine S

NCT ID: NCT06699147

Last Updated: 2024-11-21

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

238 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-09-21

Study Completion Date

2023-05-06

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study in multi-center, prospective and observational study. The purpose of this study is to observe effects and safety of hyaluronic acid filler series, eptq S and eptq Lidocaine S, for facial volume and folds.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Participants for this study are treated with eptq S and eptq Lidocaine S for smoothing nasolabial folds or volumizing mid-face or lips. Treating period is around 24 weeks. Facial volume and wrinkle condition, participants' satisfaction, and safety would be assessed.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Nasolabial Folds Mid Face Volume Loss Lip Volume Enhancement

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Nasolabial Folds

Wrinkle Severity Rating Scale(WSRS) assessed 3 or 4

Hyaluronic Acid (HA)

Intervention Type DEVICE

6 types of hyaluronic acid(HA) fillers that are differ in HA concentration and lidocaine were used for this study. Each type was applied to different condition or group depending on the investigators medical diagnosis

Mid-Face Volume

Midface Volume Deficit Scale(MFVDS) assessed 3 or higher

Hyaluronic Acid (HA)

Intervention Type DEVICE

6 types of hyaluronic acid(HA) fillers that are differ in HA concentration and lidocaine were used for this study. Each type was applied to different condition or group depending on the investigators medical diagnosis

Lip Volume

Medicis Lip Fullness Scale(MLFS) assessed 1 or 2

Hyaluronic Acid (HA)

Intervention Type DEVICE

6 types of hyaluronic acid(HA) fillers that are differ in HA concentration and lidocaine were used for this study. Each type was applied to different condition or group depending on the investigators medical diagnosis

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Hyaluronic Acid (HA)

6 types of hyaluronic acid(HA) fillers that are differ in HA concentration and lidocaine were used for this study. Each type was applied to different condition or group depending on the investigators medical diagnosis

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male and Female adults aged 19 years and older.
* Meet one of the following among individuals who want temporary improvement of facial wrinkles and volume.

1. Wrinkle Severity Rating Scale score 3 or 4 for Nasolabial fold.
2. Mid-Face Volume Deficit Scale score 3 or greater.
3. Medicis Lip Fullness Scale score 1-2. In cases of 2-1) and 2-2), participants must meet both sides (right and left) to be eligible for enrollment.

For 3), the Medicis Lip Fullness Scale scores 1-2 at the target sites for procedures (upper lip, lower lip, up \& down) eligible for enrollment
* Voluntarily agree to participate in this observational study in written consent form.

Exclusion Criteria

* Received anti-thrombotics (except low-dose aspirin \[100 mg, maximum 300 mg/day\]) within 2 weeks from screening.
* Currently have or have a history of bleeding disorder.
* applied graft/prosthesis or biomaterials, including hyaluronic acid, polycaprolactone, collagen filler, lifting (threads, laser, etc.), and Botulinum toxin, at the site for indication within 24 weeks from screening.
* Skin disorder or wound infection on the face that affects this study
* Have history of side effects of EMLA cream or equivalent lidocaine agent.
* History of hypersensitivity to hyaluronic acid agent(s).
* Other contraindications as per the \[Precautions for Use\] in the approved label for the study device.
* Determined as not eligible for the study by the investigator.
Minimum Eligible Age

19 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Jetema Co., Ltd.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Clinics

Seoul, , South Korea

Site Status

Countries

Review the countries where the study has at least one active or historical site.

South Korea

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

JT-D-OS-001

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Safety and Performance of PTMC Dermal Filler
NCT06316479 NOT_YET_RECRUITING NA